Praful Bohra of Religare Capital Markets says rupee depreciation will benefits pharma companies because they are net exporters and a lot of them do not have foreign debt.
Stock Talk:
Divis Lab is the most important beneficiary of rupee depreciation because there are no hedges. 75 per cent of their revenue comes from the US.
Lupin has a large exposure to Japan. Almost 12 per cent of the company's revenues are in yen terms. It would be negatively impacted because of depreciation in yen.
Dr Reddy's Lab has hedges between Rs 60-65. So they would probably lose some money on the lower hedges around Rs 60-61.
Praful Bohra of Religare Capital Markets says rupee depreciation will benefits pharma companies because they are net exporters and a lot of them do not have foreign debt.
Stock Talk:
Divis Lab is the most important beneficiary of rupee depreciation because there are no hedges. 75 per cent of their revenue comes from the US.
Lupin has a large exposure to Japan. Almost 12 per cent of the company's revenues are in yen terms. It would be negatively impacted because of depreciation in yen.
Dr Reddy's Lab has hedges between Rs 60-65. So they would probably lose some money on the lower hedges around Rs 60-61.
Praful Bohra of Religare Capital Markets says rupee depreciation will benefits pharma companies because they are net exporters and a lot of them do not have foreign debt.
Stock Talk:
Divis Lab is the most important beneficiary of rupee depreciation because there are no hedges. 75 per cent of their revenue comes from the US.
Lupin has a large exposure to Japan. Almost 12 per cent of the company's revenues are in yen terms. It would be negatively impacted because of depreciation in yen.
Dr Reddy's Lab has hedges between Rs 60-65. So they would probably lose some money on the lower hedges around Rs 60-61.
Sign Up with Google
RECOMMENDED FOR YOU
POPULAR